CTLA4 and cancer: Recently, Comin-Anduix et al. [42] reported that PBMCs from patients with metastatic melanoma treated with tremelimumab (fully human IgG2 mAb against CTLA-4 in clinical development for patients with cancer) were characterised by an increased level of phosphorylated form of p38MAPK (pp38MAPK).